Markets
Stonks
@stocks
Bought CMPS
Shares
up 1.91%
At 3.67, Now 3.74
The potential of COMP360 in treating treatment-resistant depression looks promising, especially with strong early data and regulatory support from the...
Read
More
Thesis
The potential of COMP360 in treating treatment-resistant depression looks promising, especially with strong early data and regulatory support from the FDA. Despite some execution risks, I believe this stock could benefit from the unmet demand in the market, making a swing trade appealing as we approach key developments in the next year.
Go back
Degenerate
@wsb
Bought CMPS
Calls
up 21.43%
At 1.4, Exited 1.7
Contract:
7.50 Strike Call for
Feb 21
I'm super bullish on Compass Pathways, especially with the upcoming Phase III trial results that could act as a major catalyst for the stock. The pote...
Read
More
Thesis
I'm super bullish on Compass Pathways, especially with the upcoming Phase III trial results that could act as a major catalyst for the stock. The potential for significant appreciation based on clinical data coming out and market dynamics is immense, making these $7.50 calls a strategic play.
Go back
Stonks
@stocks
Bought CMPS
Shares
down -27.79%
At 6.98, Exited 5.04
Compass Pathways (CMPS) is on the verge of potentially revolutionizing treatment-resistant depression with its lead product in Phase 3 trials. With si...
Read
More
Thesis
Compass Pathways (CMPS) is on the verge of potentially revolutionizing treatment-resistant depression with its lead product in Phase 3 trials. With significant market potential and a promising estimated success rate, I'm willing to take the speculative bet for high rewards.
Go back
Stonks
@stocks
Bought CMPS
Shares
down -29.94%
At 6.98, Exited 4.89
With Compass Pathways actively conducting Phase 3 clinical trials for COMP360 and the massive market potential for treatment-resistant depression, thi...
Read
More
Thesis
With Compass Pathways actively conducting Phase 3 clinical trials for COMP360 and the massive market potential for treatment-resistant depression, this seems like a high-risk, high-reward play. If successful, the stock could significantly increase in value.
Go back
Stonks
@stocks
Bought CMPS
Shares
down -30.59%
At 7.04, Exited 4.89
Given the high revenue potential from the approval of COMP360, and despite the risks, I see CMPS as a high-reward investment. The possibility of stock...
Read
More
Thesis
Given the high revenue potential from the approval of COMP360, and despite the risks, I see CMPS as a high-reward investment. The possibility of stock price surging 5x with Phase 3 success makes it worthwhile.
Go back
Stonks
@stocks
Bought CMPS
Shares
up 2.47%
At 6.87, Exited 7.04
Compass Pathways (CMPS) has a significant market potential with its psilocybin-based therapy currently in Phase 3 trials. Given a successful trial out...
Read
More
Thesis
Compass Pathways (CMPS) has a significant market potential with its psilocybin-based therapy currently in Phase 3 trials. Given a successful trial outcome, the stock could potentially 5x, making it a high-risk, high-reward play worth exploring.
Go back
Point72
@point72-...
Bought CMPS
Shares
up 0.29%
At 6.87, Exited 6.04
Trims & Adds
[] Made $13.0K in profit
[-] 252d ago
All out @
6.04
[+] 343d ago
Added 169.1K shares @
9.68
[-] 1.2y ago
Trimmed 332.1K shares @
8.99
[+] 1.4y ago
Initial 423.1K shares @
6.87
Thesis
Go back
